tradingkey.logo

Aclarion Inc

ACON
View Detailed Chart

9.400USD

+1.200+14.63%
Close 09/19, 16:00ETQuotes delayed by 15 min
5.47MMarket Cap
LossP/E TTM

Aclarion Inc

9.400

+1.200+14.63%
Intraday
1m
30m
1h
D
W
M
D

Today

+14.63%

5 Days

+21.76%

1 Month

+33.90%

6 Months

-53.97%

Year to Date

-99.28%

1 Year

-99.44%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very low. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
224 / 506
Overall Ranking
359 / 4720
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
20.000
Target Price
+143.90%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.
Growing
The company is in a growing phase, with the latest annual income totaling USD 45.72K.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 378.00 shares, decreasing 3.57% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.71K shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.
Ticker SymbolACON
CompanyAclarion Inc
CEOMr. Brent Ness
Websitehttps://aclarion.com/
KeyAI